Literature DB >> 27151127

Ustekinumab and Anti-TNF Combination Therapy in Patients with Inflammatory Bowel Disease.

Clara Yzet1, Jean-Louis Dupas1, Mathurin Fumery1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27151127     DOI： 10.1038/ajg.2016.66

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  5 in total

1.  Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.

Authors:  Robert Hirten; Randy S Longman; Brian P Bosworth; Adam Steinlauf; Ellen Scherl
Journal:  Am J Gastroenterol       Date:  2015-12       Impact factor: 10.864

2.  Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Authors:  Estelle Fréling; Cédric Baumann; Jean-François Cuny; Marc-André Bigard; Jean-Luc Schmutz; Annick Barbaud; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2015-07-21       Impact factor: 10.864

3.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease.

Authors:  William J Sandborn; Christopher Gasink; Long-Long Gao; Marion A Blank; Jewel Johanns; Cynthia Guzzo; Bruce E Sands; Stephen B Hanauer; Stephan Targan; Paul Rutgeerts; Subrata Ghosh; Willem J S de Villiers; Remo Panaccione; Gordon Greenberg; Stefan Schreiber; Simon Lichtiger; Brian G Feagan
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

4.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).

Authors:  Craig L Leonardi; Alexa B Kimball; Kim A Papp; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Shu Li; Lisa T Dooley; Kenneth B Gordon
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

5.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Authors:  Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand
Journal:  Gut       Date:  2013-03-06       Impact factor: 23.059
  5 in total
  9 in total

1.  Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Authors:  Claire Liefferinckx; Bram Verstockt; Ann Gils; Sophie Tops; Wouter Van Moerkercke; Severine Vermeire; Denis Franchimont
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

Review 2.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

3.  Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease.

Authors:  Eddie Y Liu; Dustin E Loomes
Journal:  Case Rep Med       Date:  2017-11-08

4.  Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics.

Authors:  Eric J Mao; Sara Lewin; Jonathan P Terdiman; Kendall Beck
Journal:  BMJ Open Gastroenterol       Date:  2018-11-09

Review 5.  Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor.

Authors:  Cristiano Pagnini; Theresa T Pizarro; Fabio Cominelli
Journal:  Front Pharmacol       Date:  2019-06-18       Impact factor: 5.810

6.  Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.

Authors:  Kevin J Roberts; Marion F Cubitt; Timothy M Carlton; Lurdes Rodrigues-Duarte; Luana Maggiore; Ray Chai; Simon Clare; Katherine Harcourt; Thomas T MacDonald; Keith P Ray; Anna Vossenkämper; Michael R West; J Scott Crowe
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

Review 7.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022

Review 8.  A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.

Authors:  Hang Hock Shim; Pak Wo Chan; Sai Wei Chuah; Brian J Schwender; San Choon Kong; Khoon Lin Ling
Journal:  JGH Open       Date:  2018-06-20

9.  Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.

Authors:  Laurent Goessens; Jean-Frédéric Colombel; An Outtier; Marc Ferrante; Joao Sabino; Ciaran Judge; Reza Saeidi; Louise Rabbitt; Alessandro Armuzzi; Eugeni Domenech; George Michalopoulos; Anneline Cremer; Francisco Javier García-Alonso; Tamas Molnar; Konstantinos Karmiris; Krisztina Gecse; Joep Van Oostrom; Mark Löwenberg; Klaudia Farkas; Raja Atreya; Davide Giuseppe Ribaldone; Christian Selinger; Frank Hoentjen; Benoit Bihin; Shaji Sebastian; Jean-François Rahier
Journal:  United European Gastroenterol J       Date:  2021-10-25       Impact factor: 4.623
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.